IP Library › Granted Patent US 12,318,399
Granted Patent B2
US 12,318,399 · App. 18/655,974 · Granted Jun 3, 2025

Stabilized compositions comprising cannabidiol

Inventors: Alexandra M. Capano (Philadelphia, PA); Pradeep Singh Tanwar (Fletcher, AU)
Assignees: Ecofibre USA Inc.; The University of Newcastle
A61K31/658A61K31/282A61K31/337A61K31/353A61K31/704A61K36/185A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,318,399
App. No.
18/655,974
Granted
Jun 3, 2025
Kind
B2
Abstract

Compositions and methods of use of treatment of one or more of ovarian cancer, endometrial cancer, head and neck cancer, noncancerous gynecological disorders, and estrogen sensitive cancers, the composition comprising an effective amount of a cannabinoid and a flavonoid wherein the method comprises administering to a patient in need thereof an effective amount of the composition and optionally administering the composition concomitantly with a chemotherapeutic agent.

Claims (9)

1. A method of treatment of a gynecological disease or disorder comprising administering to a patient in need thereof an effective amount of a composition comprising:

a cannabis extract and a flavonoid selected from the group consisting of: a flavonoid having the following structure:

wherein attached at each of R3, R5, R6, R7, R8, R2′, R3′, R4′, R5′, and R6′ is a hydrogen or a hydroxyl;

wherein the cannabis extract is selected from the group consisting of: a broad spectrum hemp extract, a full spectrum hemp extract, a cannabidiol (CBD) isolated, and combinations thereof;

wherein the cannabis extract comprises between 50% and 100% by weight of cannabidiol; and

wherein the ratio of the cannabis extract to the flavonoid is between 5 μg/mL: 1 μM to 5 μg/mL: 200 μM.

2. The method of claim 1 wherein the flavonoid comprises at least two hydroxyl groups attached at R3, R5, R6, R7, R8, R2′, R3′, R4′, R5′, and R6′.

3. The method of claim 1 wherein the flavonoid comprises a hydroxyl group attached at R3 and a hydroxyl group attached at at least two of R5, R6, R7, R8, R2′, R3′, R4′, R5′, and R6′.

4. The method of claim 1 further comprising a chemotherapeutic agent.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2025
From: ECOFIBRE USA, INC.
To: DOVE INNOVATION PTY LIMITED
Reel/Frame 072141/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2024
From: CAPANO, ALEXANDRA M.
To: ECOFIBRE USA INC.
Reel/Frame 067357/0054 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2024
From: TANWAR, PRADEEP SINGH
To: THE UNIVERSITY OF NEWCASTLE
Reel/Frame 067357/0106 →
Continuity (3)
Division 18493997 · Oct 25, 2023
Provisional Application 63381038 · Oct 26, 2022
Related Publication 20240293433A1 · Sep 5, 2024
References Cited (106)
US 10098867B2 · Javid et al. · 2018 [cited by applicant]
US 11123308B2 · Yu et al. · 2021 [cited by applicant]
US 20100273895A1 · Stinchcomb et al. · 2010 [cited by applicant]
US 20110086113A1 · Velasco Diez et al. · 2011 [cited by applicant]
US 20150086653A1 · Parolaro et al. · 2015 [cited by applicant]
US 20160136128A1 · Javid et al. · 2016 [cited by applicant]
US 20190282513A1 · Yerike · 2019 [cited by applicant]
US 20200253919A1 · Raz et al. · 2020 [cited by applicant]
US 20200408740A1 · Ballan et al. · 2020 [cited by applicant]
US 20210052512A1 · Guy et al. · 2021 [cited by applicant]
US 20210068444A1 · Alarcon et al. · 2021 [cited by applicant]
US 20210069608A1 · Galyuk · 2021 [cited by applicant]
US 20210085638A1 · Hospodor · 2021 [cited by applicant]
US 20210128521A1 · Palaio · 2021 [cited by applicant]
US 20210145764A1 · Lephart · 2021 [cited by applicant]
US 20220000774A1 · Dely · 2022 [cited by applicant]
US 20220054429A1 · Nathan et al. · 2022 [cited by applicant]
US 20220062224A1 · Gubler et al. · 2022 [cited by applicant]
US 20220193164A1 · White · 2022 [cited by applicant]
US 20220202765A1 · Altman et al. · 2022 [cited by applicant]
US 20220248619A1 · Kleidon · 2022 [cited by applicant]
US 20220253919A1 · Denner · 2022 [cited by applicant]
US 20220331287A1 · Morgan et al. · 2022 [cited by applicant]
US 20230015268A1 · Altman et al. · 2023 [cited by applicant]
US 20230127098A1 · Capano et al. · 2023 [cited by applicant]
US 20230132189A1 · Capano et al. · 2023 [cited by applicant]
US 20230248747A1 · Altman et al. · 2023 [cited by applicant]
US 20230355645A1 · Storch et al. · 2023 [cited by applicant]
CN 108433880A · 2018 [cited by applicant]
CN 110063953A · 2019 [cited by applicant]
EP 3368024A1 · 2018 [cited by applicant]
EP 3449992A1 · 2019 [cited by applicant]
EP 3544598A1 · 2019 [cited by applicant]
EP 3915550A1 · 2021 [cited by applicant]
EP 3937914A1 · 2022 [cited by applicant]
GB 2516335A · 2015 [cited by applicant]
RU 2745687C1 · 2021 [cited by applicant]
WO WO2013165251A1 · 2013 [cited by applicant]
WO WO2014057067A1 · 2014 [cited by applicant]
WO WO2016187679A1 · 2016 [cited by applicant]
WO WO2017072773A1 · 2017 [cited by applicant]
WO WO2018167038A1 · 2018 [cited by applicant]
WO WO2019003163A2 · 2019 [cited by applicant]
WO WO2019034113A1 · 2019 [cited by applicant]
WO WO2019106652A1 · 2019 [cited by applicant]
WO WO2019145552A1 · 2019 [cited by applicant]
WO WO2019195943A1 · 2019 [cited by applicant]
WO WO2019222459A1 · 2019 [cited by applicant]
WO WO2020036655A9 · 2020 [cited by applicant]
WO WO2020163775A1 · 2020 [cited by applicant]
WO WO2020165878A1 · 2020 [cited by applicant]
WO WO2020183455A1 · 2020 [cited by applicant]
WO WO2020194237A1 · 2020 [cited by applicant]
WO WO2020209902A1 · 2020 [cited by applicant]
WO WO2021011790A1 · 2021 [cited by applicant]
WO WO2021016718A1 · 2021 [cited by applicant]
WO WO2021028646A1 · 2021 [cited by applicant]
WO WO2021099792A1 · 2021 [cited by applicant]
WO WO2021130728A1 · 2021 [cited by applicant]
WO WO2021158251A1 · 2021 [cited by applicant]
WO WO2021235977A1 · 2021 [cited by applicant]
WO WO2021240510A1 · 2021 [cited by applicant]
WO WO2021245522A1 · 2021 [cited by applicant]
WO WO2022011393A1 · 2022 [cited by applicant]
WO WO2022013854A1 · 2022 [cited by applicant]
WO WO2022016160A1 · 2022 [cited by applicant]
WO WO2022018708A1 · 2022 [cited by applicant]
WO WO2022105952A1 · 2022 [cited by applicant]
WO WO2022118303A1 · 2022 [cited by applicant]
WO WO2022144878A1 · 2022 [cited by applicant]
WO WO2022165349A1 · 2022 [cited by applicant]
WO WO2022165439A1 · 2022 [cited by applicant]
WO WO2022201043A1 · 2022 [cited by applicant]
WO WO2022204422A1 · 2022 [cited by applicant]
WO WO2022215071A1 · 2022 [cited by applicant]
WO WO2022225658A1 · 2022 [cited by applicant]
WO WO2023287742A1 · 2023 [cited by applicant]
WO WO2023014818A2 · 2023 [cited by applicant]
WO WO2023062634A1 · 2023 [cited by applicant]
Tomko et al, Anti-cancer properties of cannflavin A and potential synergistic. effects with gemcitabine, cisplatin, and cannabinoids in bladder cancer. Journal of Cannabis Research, (Jul. 22, 2022) vol. 4, No. 1, pp. 1-… [cited by examiner]
International Search Report issued in International Application No. PCT/US2023/077706 dated Feb. 28, 2024. [cited by applicant]
Armour, et al., “Self-Management Strategies Amongst Australian Women With Endometriosis: A National Online Survey”, BMC Complementary and Alternative Medicine, vol. 19, No. 1, art. 17, Jan. 15, 2019, 1-8. [cited by applicant]
Escudero-Lara, et al., “Disease-Modifying Effects of Natural Δ [cited by applicant]
Fonseca, et al., “Cannabinoid-Induced Cell Death in Endometrial Cancer Cells: Involvement of TRPV1 Receptors in Apoptosis”, Journal of Physiology and Biochemistry, vol. 74, No. 2, Feb. 13, 2018, 261-272. [cited by applicant]
Fraguas-Sánchez, et al., “Enhancing Ovarian Cancer Conventional Chemotherapy Through the Combination With Cannabidiol Loaded Microparticles”, European Journal of Pharmaceutics and Biopharmaceutics, vol. 154, Jul. 17, 20… [cited by applicant]
Go, et al., “Cannabidiol Enhances Cytotoxicity of Anti-Cancer Drugs in Human Head and Neck Squamous Cell Carcinoma”, Scientific Reports, vol. 10, No. 1, art. 20622, Nov. 26, 2020, 1-11. [cited by applicant]
Griffiths, et al., “Cannabidiol Suppresses 3-Dimensional Ovarian Cancer Growth and May Enhance Potency of Classic and Epigenetic Therapies”, Gynecologic Oncology, vol. 162, suppl. 1, Abstracts for the 2021 Society of Gy… [cited by applicant]
Hazekamp, et al., “Preparative Isolation of Cannabinoids from Cannabis sativa by Centrifugal Partition Chromatography”, Journal of Liquid Chromatography & Related Technologies, vol. 27, No. 15, 2004, 2421-2439. [cited by applicant]
Jaidee, et al., “Kinetics of CBD, Δ [cited by applicant]
Jin, et al., “Identification of Chemotypic Markers in Three Chemotype Categories of Cannabis Using Secondary Metabolites Profiled in Inflorescences, Leaves, Stem Bark, and Roots”, Frontiers in Plant Science, vol. 12, ar… [cited by applicant]
Kenyon, et al., “Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-Grade Synthetic Cannabidiol”, Anticancer Research, vol. 38, No. 10, Oct. 1, 2018, 5831-5835. [cited by applicant]
Lazarjani, et al., “Processing and Extraction Methods of Medicinal Cannabis: A Narrative Review”, Journal of Cannabis Research, vol. 3, art. 32, Jul. 19, 2021, 1-15. [cited by applicant]
Marinelli, et al., “The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer”, International Journal of Molecular Sciences, vol. 21, No. 15, art. 5409, Jul. 29, 2020, 1-22. [cited by applicant]
Marinotti, et al., “Differentiating Full-Spectrum Hemp Extracts from CBD Isolates: Implications for Policy, Safety and Science”, Journal of Dietary Supplements, vol. 17, No. 5, Jun. 16, 2020, 517-526. [cited by applicant]
Midatech Pharma US Inc., Soltamox® Product Label, Revised Apr. 2019. [cited by applicant]
Ökten, et al., “Cannabidiol as a Potential Novel Treatment for Endometriosis by Its Anti-Inflammatory and Anti- Oxidative Effects in an Experimental Rat Model”, Human Reproduction, vol. 37, issue supp. 1, Jun. 30, 2022,… [cited by applicant]
Olivas-Aguirre, et al., “Tamoxifen Sensitizes Acute Lymphoblastic Leukemia Cells to Cannabidiol by Targeting Cyclophilin-D and Altering Mitochondrial Ca [cited by applicant]
Rais, et al., “Phytochemicals in the Treatment of Ovarian Cancer”, Frontiers in Bioscience-Elite, vol. 9, No. 1, Jan. 1, 2017, 67-75. [cited by applicant]
Raskin, et al., “Can an Apple a Day Keep the Doctor Away?”, Current Pharmaceutical Design, vol. 10, No. 27, Feb. 2004, 3419-3429. [cited by applicant]
Rush, et al., “Cannabidiol: Assessing Activity in Ovarian and Endometrial Carcinoma Cell Lines”, Abstracts for the 2021 Society of Gynecologic Oncology 52nd Annual Meeting on Women's Cancer, Featured Posters 188—Poster … [cited by applicant]
Sumanasekera, et al., “Hemp Extract With Specific Anti-Cancer Properties Against Ovarian Cancer”, The FASEB Journal Special Issue: Experimental Biology 2021 Meeting Abstracts, vol. 35, No. S1, May 14, 2021, https://doi.… [cited by applicant]
Tallarida, “Quantitative Methods for Assessing Drug Synergism”, Genes & Cancer, vol. 2, No. 11, Apr. 19, 2012, 1003-1008. [cited by applicant]
Tomko, et al., “Anti-Cancer Properties of Cannflavin A and Potential Synergistic Effects With Gemcitabine, Cisplatin, and Cannabinoids in Bladder Cancer”, Journal of Cannabis Research, vol. 4, art. 41, Jul. 22, 2022, 1-… [cited by applicant]
Van Weelden, et al., “Anti-Estrogen Treatment in Endometrial Cancer: A Systematic Review”, Frontiers in Oncology, vol. 9, art. 359, May 7, 2019, 1-12. [cited by applicant]
Boretto, et al., “Patient-Derived Organoids From Endometrial Disease Capture Clinical Heterogeneity and Are Amenable to Drug Screening”, Nature Cell Biology, vol. 21, Aug. 1, 2019, 1041-1051. [cited by applicant]
Fraguas-Sánchez, Ana I., et al., “PLGA Nanoparticles for the Intraperitoneal Administration of CBD in the Treatment of Ovarian Cancer: In Vitro and In Ovo Assessment”, Pharmaceutics, vol. 12, No. 5, art. 439, May 9, 202… [cited by applicant]